ClinicalTrials.gg
TerminatedNCT04417517Updated Jul 20, 2025

A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)

A Phase 1 interventional study of evorpacept and azacitidine in Higher Risk Myelodysplastic Syndromes, sponsored by ALX Oncology Inc.. Terminated at 19 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-20.

Sponsored by ALX Oncology Inc. · Phase 1, Interventional, and Treatment

Why this study was terminated
While intended to be a Phase 1/2 clinical study, the study did not proceed to Phase 2.

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,363 studies in Myelodysplastic Syndromes with a site in United States — 174 open to participants now, 279 under way, 17 of them phase 3. Myelodysplastic Syndromes · United States.

Enrollment
345th of 1,189
65 · median 35
Started
2020
with 57 others
Phase 1
384 of 1,363
56 open now
Registered
1,121st of 1,363
by date

Among the 1,363 studies in Myelodysplastic Syndromes with a site in United States, this one is the 345th largest by enrollment of the 1,189 interventional ones that give a count, is one of 58 that started in 2020, is one of 384 in phase 1, and was the 1,121st registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

174 of the 1,363 studies in Myelodysplastic Syndromes with a site in United States are open now. Recruiting first, the newest first:

169 more — sign in →

All 174 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,363 studies in Myelodysplastic Syndromes with a site in United States, or all of them as a file.
02

Study summary

This Phase 1/2 clinical study will evaluate evorpacept (ALX148) in combination with azacitidine for the treatment of patients with higher risk myelodysplastic syndrome (MDS).

Read the detailed description

The Phase 1 will consist of a dose escalation of evorpacept (ALX148) in combination with azacitidine to evaluate safety and tolerability, and to identify the recommended Phase 2 dose of ALX148 in combination with azacitidine. The Phase 2 will evaluate the efficacy of evorpacept (ALX148) in combination with azacitidine compared to azacitidine alone for patients with previously untreated higher risk MDS.

03

Conditions studied

  • Higher Risk Myelodysplastic Syndromes

Keywords

  • ALX148
  • MDS
  • CD47
  • Azacitidine
  • HMA
  • SIRP-alpha
  • evorpacept
  • High risk
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Phase 1: Diagnosis of higher risk MDS that is either previously untreated or .
  • Phase 2: Diagnosis of higher risk MDS that is previously untreated.
  • Adequate renal and liver function.
  • Age ≥18 years.
  • Adequate performance status.

Exclusion criteria

Exclusion Criteria:

  • Previous hematopoietic stem cell transplant (allo-HSCT) for MDS or AML.
  • Prior treatment with any anti-7 or anti-SIRPα (signal regulatory protein alpha) agent.
  • Known active viral infections, including and C, (HIV), acquired immunodeficiency syndrome (AIDS) related illness, or SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    evorpacept (ALX148) + azacitidine

    Phase 1: Participants will receive escalating doses of evorpacept (ALX148) in combination with azacitidine 75 mg/m2 IV or subcutaneous daily for 7 days of a 28 day cycle Phase 2: Participants will receive evorpacept (ALX148) at the recommended Phase 2 dose in combination with azacitidine 75 mg/m2 IV or subcutaneous daily for 7 days of a 28-day cycle

    Drug: evorpacept · Drug: azacitidine

  • Active comparator
    azacitidine

    Phase 2 only: Participants will receive azacitidine 75 mg/m2 IV or subcutaneous daily for 7 days of a 28-day cycle

    Drug: azacitidine

Interventions

  • Fusion protein that blocks CD47-SIRPalpha pathway

    Also known as: ALX148

  • Hypomethylating agent (HMA)

    Also known as: Vidaza

06

What researchers measure

Primary outcomes

  1. Phase 1: Dose Limiting Toxicities (DLT)

    Number of participants with a DLT

    Time frame: Up to 28 days

  2. Phase 1: Recommended Phase 2 Dose (RP2D)

    To identify the RP2D of ALX148 in combination with AZA

    Time frame: Approximately 2 years

  3. Phase 2: Complete response rate (CRR)

    Number of participants achieving a complete response per International Working Group (IWG) criteria

    Time frame: Approximately 6 months

07

Study locations

19 sites
  • University of Southern California, Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • IU Simon Cancer Center
    Indianapolis, Indiana 46202, United States
  • START Midwest
    Grand Rapids, Michigan 49546, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37203, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
  • Asan Medical Center
    Seoul, South Korea
  • Samsung Medical Center
    Seoul, South Korea
  • Seoul National University Hospital
    Seoul, South Korea
  • Seoul Saint Mary's Hospital
    Seoul, South Korea
  • Severance Hospital
    Seoul, South Korea
  • Hospital General Universitario de Alicante
    Alicante, 03010, Spain
  • Hospital San Pedro de Alcantara
    Cáceres, 10003, Spain
  • Hospital Universitario de Salamanca
    Salamanca, 37007, Spain
  • Hospital Universitari i Politecnic La Fe de Valencia
    Valencia, 46026, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Jan 2025, 51 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2020
First posted
Jun 4, 2020
StartActual
Oct 2, 2020
Primary completionActual
Jan 17, 2025
CompletionActual
Jun 10, 2025
Last update
Jul 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04417517
Lead sponsor
ALX Oncology Inc.
Responsible party
Sponsor
First posted
Jun 4, 2020
Start date
Oct 2, 2020
Primary completion
Jan 17, 2025
Completion
Jun 10, 2025
Last update
Jul 20, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ALX148

Start the discussion